BioNTech Secures $145M from CEPI to Expand mRNA Vaccine Production in Africa

1. CEPI Funding: BioNTech has received $145 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to expand its mRNA vaccine production capabilities in Africa.
2. Africa Expansion: The funding aims to enhance local research and development, clinical, and commercial-scale manufacturing capacities for mRNA vaccines in Africa.
3. Moderna Criticism: The Africa CDC has criticized Moderna for halting plans to build a vaccine plant in Kenya, citing a lack of commitment to vaccine equity and access in Africa.
4. Vaccine Demand: Moderna has reported declining vaccine sales, citing insufficient demand to support the viability of the planned factory in Kenya.
5. BioNTech's Commitment: BioNTech, on the other hand, is moving forward with its plans to strengthen Africa's mRNA vaccine ecosystem, demonstrating a commitment to vaccine equity and access.